Latest Supply Agreements News

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

Sprintex Limited reported a 162% surge in revenue to A$2.7 million for the half-year ending December 2025, driven by a landmark €15.6 million European contract. Despite this, the company posted a net loss of A$1.7 million, an improvement from the prior year, while raising $3.6 million to support global expansion.

Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.

Coronado Global Resources reported a $432.1 million net loss for FY2025, impacted by a 22% revenue decline due to softer metallurgical coal markets and logistical challenges. Despite operational gains and cost cuts, the company strengthened liquidity through refinancing and support from Stanwell.

Inghams Group reports flat revenue but a sharp 42% drop in EBITDA for the first half of FY26, revising full-year earnings guidance lower amid ongoing cost inflation and operational challenges.

Elevra Lithium reported solid Q2 FY26 production and revenue results while progressing its North American Lithium brownfield expansion and forging strategic supply partnerships.

Cleo Diagnostics has chosen Bio-Techne’s next-generation Ella™ platform to enhance its ovarian cancer blood test, aiming for faster, more precise results and a streamlined path to FDA approval.

Strike Energy has secured all regulatory approvals to drill the Walyering West-1 well in the Perth Basin, aiming to unlock a prospective 46 PJ gas resource with drilling set to commence by mid-April 2026.

The a2 Milk Company has reported robust half-year results with strong revenue and earnings growth, driven by gains in infant formula and liquid milk segments, alongside a strategic supply chain transformation. The company has upgraded its full-year outlook and announced a substantial special dividend, signalling confidence in its growth trajectory.

Amaero Ltd reported a remarkable 367% revenue increase to A$7.76 million for H1 FY2026, supported by a $50 million capital raise and exclusive supply agreements with industry leaders. Despite widening losses, the company is accelerating capacity expansion and securing key partnerships in aerospace and defence.

AGL Energy reported a steady first half with flat underlying EBITDA and a narrowed FY26 earnings outlook, while accelerating its renewable projects and forming a strategic partnership with Aussie Broadband.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.